ClinicalTrials.gg
CompletedNCT03289208Updated Jul 15, 2026Results posted

Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment

A Phase 1 interventional study of MCI-186 in Renal Impairment and Healthy, sponsored by Shionogi. Completed at 1 site in Japan. Open to participants aged 20 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Shionogi · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Oct 2016, registered Sep 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies in Renal Insufficiency with a site in Japan — 1 open to participants now, 3 under way, 1 of them phase 3. Renal Insufficiency · Japan.

Enrollment
20th of 31
30 · median 35
Started
2016
the only one that year
Phase 1
9 of 39
none open now
Registered
36th of 39
by date

Among the 39 studies in Renal Insufficiency with a site in Japan, this one is the 20th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2016, is one of 9 in phase 1, and was the 36th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

1 of the 39 studies in Renal Insufficiency with a site in Japan is open now. Recruiting first, the newest first:

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Renal Insufficiency with a site in Japan, or all of them as a file.
02

Study summary

To assess the pharmacokinetics of MCI-186 after a single intravenous infusion of 30mg/hour in subjects with mild or moderate renal impairment compared to subjects with normal renal function.

03

Conditions studied

  • Renal Impairment
  • Healthy

Browse trials for

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects

  • Able to provide written to participate in this study after reading the ICF
  • Subjects is able to understand and willing to cooperate and comply with the Protocol restrictions and requirements
  • A body weight of ≥45 kg in males or ≥40 kg in females and a ranging from 18 to 30 kg/m2

Renal impaired subjects (in addition)

  • Subjects with mild renal impairment defined as 60-89 mL/min/1.73m2 and subjects with moderate renal impairment defined as eGFR 30-59 mL/min/1.73m2
  • Chronic and stable renal impairment

Healthy subjects (in addition)

  • Subject with normal renal function defined as eGFR≥90 mL/min/1.73m2
  • Good health and free from illness or disease

Exclusion criteria

Exclusion Criteria:

All subjects

  • Presence or history of severe allergy to food, or any medicinal product or relevant that is of clinical significance
  • Subjects were previously administered MCI-186
  • Positive urine drug screen (if not due to concomitant medication) or alcohol test
  • History of alcohol abuse or drug abuse
  • Presence of active infection requiring antibiotics
  • Positive test for (HIV) antigen/antibody, surface antigen (HBsAg), or virus antibody (HCVAb)

Renal impairment subject (in addition)

  • Acute renal failure
  • History of renal transplantation
  • (AST) activity, or an alanine aminotransferase (ALT) activity of at least 3 times the (ULN) range
  • Uncontrolled, or untreated hypertension defined as systolic blood pressure (SBP)>180 mmHg and/or diastolic blood pressure (DBP)>110 mmHg
  • Start of any new medication or new any changes to a current dosage

Healthy subject (in addition)

  • History or presence of any renal disease
  • Uncontrolled, or untreated hypertension defined as systolic blood pressure (SBP)>160 mmHg and/or diastolic blood pressure (DBP)>100 mmHg
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    mild renal impairment

    Drug: MCI-186

  • Experimental
    moderated renal impairment

    Drug: MCI-186

  • Experimental
    normal renal function

    Drug: MCI-186

Interventions

  • 30 mg of edaravone will be administered intravenously over 60 minutes.

    Also known as: Edaravone, Radicut

06

What researchers measure

Primary outcomes

  1. Cmax

    Time frame: pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose

  2. AUC0-last

    Time frame: pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose

  3. AUC0-∞

    Time frame: pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose

Secondary outcomes

  1. t½

    Time frame: pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose

07

Results

Posted Feb 28, 2020

Participant flow

Participant flow — Overall Study
MilestoneMild Renal Function GroupModerate Renal Function GroupNormal Renal Function Group
Started11811
Completed10811
Not completed100
Withdrew: Adverse event100

Outcome measures

PrimaryCmax
Time frame:
pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose
Reported as:
Mean · ng/mL
Cmax
ng/mLMild Renal Function GroupModerate Renal Function GroupNormal Renal Function Group
Cmax545.4 ± 92.59593.2 ± 115.4475.9 ± 95.32
PrimaryAUC0-last
Time frame:
pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose
Reported as:
Mean · ng*hr/mL
AUC0-last
ng*hr/mLMild Renal Function GroupModerate Renal Function GroupNormal Renal Function Group
AUC0-last758 ± 148.09808.7 ± 152.01638.09 ± 151.98
PrimaryAUC0-∞
Time frame:
pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose
Reported as:
Mean · ng*hr/mL
AUC0-∞
ng*hr/mLMild Renal Function GroupModerate Renal Function GroupNormal Renal Function Group
AUC0-∞770.97 ± 153.63826.44 ± 149.44644.85 ± 153.14
Secondaryt½
Time frame:
pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose
Reported as:
Mean · hour
t½
hourMild Renal Function GroupModerate Renal Function GroupNormal Renal Function Group
t½5.38 ± 6.047.31 ± 5.832.87 ± 0.38

Adverse events

Collected over 7 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mild Renal Function Group0/11 (0%)0/11 (0%)5/11 (45.5%)
Moderate Renal Function Group0/8 (0%)0/8 (0%)0/8 (0%)
Normal Renal Function Group0/11 (0%)0/11 (0%)1/11 (9.1%)
Most frequent other events
Most frequent other events
EventMild Renal Function GroupModerate Renal Function GroupNormal Renal Function Group
HeadacheNervous system disorders2/110/80/11
BronchitisInfections and infestations1/110/80/11
VomittingGastrointestinal disorders1/110/80/11
HaematuriaRenal and urinary disorders1/110/80/11
Aspartate aminotransferase increasedInvestigations0/110/81/11
Blood bilirubin increasedInvestigations1/110/80/11

Baseline characteristics

Age, Continuous
Age, Continuous(years)Mild Renal Function GroupModerate Renal Function GroupNormal Renal Function GroupTotal
Mean35.5 ± 5.157.9 ± 8.447.3 ± 4.345.8 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Mild Renal Function GroupModerate Renal Function GroupNormal Renal Function GroupTotal
Female5229
Male66921
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Mild Renal Function GroupModerate Renal Function GroupNormal Renal Function GroupTotal
American Indian or Alaska Native0000
Asian1181130
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
08

Study locations

1 site
  • Investigational site
    Tokyo, Japan
09

References and documents

Publications

  • Nakamaru Y, Kakubari M, Yoshida K, Akimoto M, Kondo K. An Open-label, Single-dose Study to Evaluate the Pharmacokinetic Variables of Edaravone in Subjects with Mild, Moderate, or No Renal Impairment. Clin Ther. 2020 Sep;42(9):1699-1714. doi: 10.1016/j.clinthera.2020.06.020. Epub 2020 Aug 28. PubMed 32868037 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Apr 2018, 17 months.

Results were first posted in Feb 2020, 1 year 10 months after primary completion.

Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 17 months is above that.

Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2017
First posted
Sep 20, 2017
StartActual
Oct 27, 2016
Primary completionActual
Apr 16, 2018
CompletionActual
Apr 20, 2018
Results first posted
Feb 28, 2020
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03289208
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Sep 20, 2017
Start date
Oct 27, 2016
Primary completion
Apr 16, 2018
Completion
Apr 20, 2018
Results posted
Feb 28, 2020
Last update
Jul 15, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edaravone

Start the discussion